Navigation Links
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Date:10/3/2011

logic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.

The Company recently completed a $25.8 million round of financing and is using the proceeds to advance its pipeline, including funding Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease scheduled for initiation in early 2012 and a Phase I/II dose escalation and expansion trial of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML) planned for 2012.  Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs.

Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or r
'/>"/>

SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Coronado Biosciences Closes $25.8M in Series C Financing
3. Coronado Biosciences Files to Become a Public Reporting Company
4. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine ... announced the business and development progress at its Jiangchuan ... the September 2014 JCM application (No. 51268) for the ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) ... Diagnostics Market by Product, Application, Technology, End User - ... , The infectious disease diagnostics market is ... $18,156.2 million by 2019 from $12,422.8 million in 2014. ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... Baxter,International Inc. today announced final Phase I/II data ... to initiate a Phase III clinical trial of ... results. , The Phase I/II study indicated that ... doses, and induces substantial,levels of cross immunity against ...
... Dr. H. Bryan Brewer, Jr. Sees Enormous Potential ... (MARKET WIRE via COMTEX News Network),-- Lipid Sciences, ... Scientific Director of Lipid Sciences, Inc., concluded from,the ... College of,Cardiology (ACC) Meeting in New Orleans that ...
Cached Medicine Technology:Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... 22, 2015 State Forestry Institute of ... system with support from GEOSYSTEMS, a dedicated Hexagon Geospatial ... will leverage Hexagon Geospatial’s ERDAS APOLLO for ... well as point clouds and documents. This effort will ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... LA CROSSE, Wis., April 21 When Gundersen Lutheran Health ... for the 1 to 2 percent decrease that,s common at ... more reduction in less than two years. That,s 9,600 metric ... the environment, the equivalent of removing 1,631 cars from the ...
... NeoGenomics, Inc. (NASD OTC BB: NGNM) ... quarter 2009 financial results on Thursday, April 23, 2009.The Company ... Q1 2009 results on April 23, 2009, at 11:00 AM ... (201) 689-8049 (international) at least five minutes prior to the ...
... Exposition Park LOS ANGELES, ... Dimes premier fundraising event that benefits all babies--those born healthy ... walkers are expected at this largest March for Babies event ... at the corner of S. Figueroa and 39th St., Los ...
... Features Gold Glove Outfielder Nate McLouth, Three Teen ... in partnership with the Pittsburgh Pirates baseball club ... the launch of a new campaign designed to ... infection MRSA and how regular hand-washing can help ...
... Seven years after becoming the Midwest,s first graduate school ... Chicago School of Professional Psychology is expanding its forensic ... to advance their career in the law and legal sectors. ... this fall at the school,s Chicago Campus at 325 N. ...
... had reduced risk of relapse or death, study finds ... non-Hodgkin lymphoma who drank wine before their diagnosis appeared ... according to a study that,s the first to identify ... 500 women with non-Hodgkin lymphoma and found that, overall, ...
Cached Medicine News:Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009 2Health News:NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009 3Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Pittsburgh Hospital Teams with Pirates Baseball Club in Unique Effort to Encourage Teen Handwashing, Prevent Spread of MRSA 2Health News:Pittsburgh Hospital Teams with Pirates Baseball Club in Unique Effort to Encourage Teen Handwashing, Prevent Spread of MRSA 3Health News:The Chicago School of Professional Psychology Announces Nation's First Psy.D. Program in Clinical Forensic Psychology 2Health News:The Chicago School of Professional Psychology Announces Nation's First Psy.D. Program in Clinical Forensic Psychology 3Health News:Wine May Guard Against Lymphoma Recurrence 2
Open 11 mm blades. Dull finish. Most popular size or model....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 11 mm blades. Polished finish....
Open 10 mm blades. Dull finish....
Medicine Products: